Abstract
AbstractThe difficulties in purification of VLP-based recombinant hepatitis B surface antigen (rHBsAg) are mainly emerged from inefficient semi-purification step plus proteins physicochemical properties and these issues make the downstream processing (DSP) very lengthy and expensive. In this study, optimization of rHBsAg (recombinantly-expressed in Pichia pastoris) DSP was performed using selection of buffering conditions in the semi-purification step. In the semi-purification optimization step, up to 73% of the protein impurities were eliminated and the utmost increase in rHBsAg purity (ca. 3.6-fold) was achieved using 20 mM sodium acetate, pH 4.5. By using rHBsAg binding and nonbinding situations obtained from the response surface plot in design of experiments (DOE), additional bind-elute and flow-through purification mode experiments were conducted and rHBsAg with high purity (near 100%) and recovery (> 83%) was achieved. Following assessment of critical quality attributes (i.e., purity, particle size distribution, host cell DNA, host cell protein, secondary structures, specific activity and relative potency), it was indicated that the characteristics of rHBsAg purified by the new DSP were similar or superior to the ones obtained from conventional DSP. The purification performance of the resin was constantly retained (97–100%) and no significant resin damage took place after 10 adsorption–elution–cleaning cycles. The new DSP developed for production of rHBsAg in this study can substitute the conventional one with granting satisfactory target protein quality, long-lasting resin efficacy, shorter and less expensive process. This process may be also employable for purification of both non-VLP- and VLP- based target proteins expressed in the yeast.
Funder
Pasteur Institute of Iran
Pasteur institute of Iran
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. WHO. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b#. Hepatitis B is a potentially,from cirrhosis and liver cancer. (2020).
2. Patil, A. & Khanna, N. Novel membrane extraction procedure for the purification of hepatitis B surface antigen from Pichia pastoris. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 898, 7–14 (2012).
3. Jürgens, M. C. et al. The hepatitis B virus preS1 domain hijacks host trafficking proteins by motif mimicry. Nat. Chem. Biol. 9, 540–547 (2013).
4. Maupas, P., Goudeau, A. & Bagros, P. Immunisation against hepatitis B in man. Lancet 7, 1367–1370 (1974).
5. Stephenne, J. Recombinant versus plasma-derived hepatitis B vaccines: Issues of safety, immunogenicity and cost-effectiveness. Vaccine 6, 299–303 (1988).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献